The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma
Biological and Pharmaceutical Bulletin 29 巻 11 号
2331-2334 頁
2006-11 発行
アクセス数 : 648 件
ダウンロード数 : 194 件
今月のアクセス数 : 1 件
今月のダウンロード数 : 0 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00047053
ファイル情報(添付) |
BiolPhamBull_29_2331.pdf
109 KB
種類 :
全文
|
タイトル ( eng ) |
The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma
|
作成者 |
Kamikawa Rintaro
Asaoku Hideki
Iwato Koji
Sasaki Ayako
|
収録物名 |
Biological and Pharmaceutical Bulletin
|
巻 | 29 |
号 | 11 |
開始ページ | 2331 |
終了ページ | 2334 |
抄録 |
Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response. The aim of this study was to characterize the pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, and to examine the relationship between pharmacokinetics and adverse events. On the first and second days, a 100 mg capsule was administered to 8 Japanese patients after breakfast and blood samples were obtained. The plasma concentrations were measured using HPLC and analyzed based on a one-compartment model. If intolerable adverse events were not observed for 14 d, the dose was increased to 200 mg. The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration–time curve from 0 to infinity (AUC0—∞), which were 45.3 l, 5.5 l/h and 21.7 μg·h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0—∞ than in Caucasian populations. This pharmacokinetic difference may explain the dose difference between Japan and other countries. Adverse events were associated with AUC0—∞, which was best correlated with plasma concentration at 12 h after administration. The 12-h time point was suggested to be a capable indicator for “safety-oriented” therapeutic drug monitoring of thalidomide.
|
著者キーワード |
thalidomide
pharmacokinetics
multiple myeloma
|
NDC分類 |
医学 [ 490 ]
|
言語 |
英語
|
資源タイプ | 学術雑誌論文 |
出版者 |
The Pharmaceutical Society of Japan
|
発行日 | 2006-11 |
権利情報 |
© 2006 Pharmaceutical Society of Japan
|
出版タイプ | Version of Record(出版社版。早期公開を含む) |
アクセス権 | オープンアクセス |
収録物識別子 |
[ISSN] 0918-6158
[ISSN] 1347-5215
[NCID] AA10885497
[DOI] 10.1248/bpb.29.2331
[DOI] https://doi.org/10.1248/bpb.29.2331
|